Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

1. Male and female subjects aged 18-70 years;
2. Confirmed diagnosis of ulcerative colitis (UC) prior to IPAA, with pouch takedown completed for at least 3 months;
3. Patients with pouchitis and an mPDAI score ≥ 5 points;
4. Positive stool test for MTB bacteria or Aeromonas aerolysin;
5. Subjects who agree to participate in this clinical study and have provided written informed consent.

1. Patients with pre-operative diagnosis of familial polyposis, Crohn's disease, or indeterminate colitis;
2. Subjects who underwent temporary or permanent ileostomy without pouch construction;
3. Active cardiovascular and cerebrovascular diseases including coronary heart disease, hypertension, cerebral infarction;
4. Patients suffering from other systemic diseases, autoimmune diseases, malignant tumors, or other severe chronic illnesses;
5. History of psychotropic substance abuse;
6. Pregnant or lactating women;
7. Recent use of probiotic therapy;
8. Patients who have received antibiotics within the past three months;
9. Subjects deemed unsuitable for participation in this study at the investigator's discretion.

Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)